Cozad Asset Management Inc. Has $9.02 Million Stock Holdings in HCA Healthcare, Inc. (NYSE:HCA)

Cozad Asset Management Inc. grew its position in HCA Healthcare, Inc. (NYSE:HCA) by 0.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 30,044 shares of the company’s stock after purchasing an additional 126 shares during the period. Cozad Asset Management Inc.’s holdings in HCA Healthcare were worth $9,018,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Counterpoint Mutual Funds LLC boosted its stake in shares of HCA Healthcare by 78.9% in the 4th quarter. Counterpoint Mutual Funds LLC now owns 4,582 shares of the company’s stock valued at $1,375,000 after purchasing an additional 2,021 shares in the last quarter. Cibc World Markets Corp raised its holdings in shares of HCA Healthcare by 13.1% in the fourth quarter. Cibc World Markets Corp now owns 29,268 shares of the company’s stock valued at $8,785,000 after buying an additional 3,383 shares during the last quarter. SouthState Corp raised its holdings in shares of HCA Healthcare by 1,211.8% in the fourth quarter. SouthState Corp now owns 3,778 shares of the company’s stock valued at $1,134,000 after buying an additional 3,490 shares during the last quarter. IMG Wealth Management Inc. bought a new position in shares of HCA Healthcare in the fourth quarter valued at about $136,000. Finally, Gallacher Capital Management LLC raised its holdings in shares of HCA Healthcare by 4.9% in the fourth quarter. Gallacher Capital Management LLC now owns 1,679 shares of the company’s stock valued at $504,000 after buying an additional 79 shares during the last quarter. Institutional investors and hedge funds own 62.73% of the company’s stock.

Insider Transactions at HCA Healthcare

In other news, SVP Jennifer Berres sold 9,533 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $322.59, for a total transaction of $3,075,250.47. Following the sale, the senior vice president now owns 15,412 shares in the company, valued at $4,971,757.08. This represents a 38.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 1.60% of the company’s stock.

HCA Healthcare Price Performance

Shares of HCA opened at $319.82 on Monday. HCA Healthcare, Inc. has a 52-week low of $289.98 and a 52-week high of $417.14. The company has a debt-to-equity ratio of 69.07, a quick ratio of 0.97 and a current ratio of 1.08. The stock has a 50 day simple moving average of $319.00 and a 200 day simple moving average of $344.95. The firm has a market capitalization of $78.74 billion, a PE ratio of 14.56, a P/E/G ratio of 1.10 and a beta of 1.68.

HCA Healthcare (NYSE:HCA) last released its quarterly earnings results on Friday, January 24th. The company reported $6.22 earnings per share for the quarter, topping analysts’ consensus estimates of $6.03 by $0.19. HCA Healthcare had a return on equity of 586.47% and a net margin of 8.16%. During the same quarter in the prior year, the company posted $5.90 earnings per share. Sell-side analysts predict that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 17th will be paid a dividend of $0.72 per share. The ex-dividend date is Monday, March 17th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.90%. This is a boost from HCA Healthcare’s previous quarterly dividend of $0.66. HCA Healthcare’s dividend payout ratio is currently 13.11%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Barclays cut their price target on HCA Healthcare from $392.00 to $366.00 and set an “overweight” rating for the company in a report on Monday, January 27th. Bank of America dropped their price objective on HCA Healthcare from $380.00 to $370.00 and set a “buy” rating for the company in a report on Monday, January 27th. Morgan Stanley dropped their price objective on HCA Healthcare from $406.00 to $355.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Truist Financial dropped their price objective on HCA Healthcare from $430.00 to $390.00 and set a “buy” rating for the company in a report on Monday, January 6th. Finally, Wells Fargo & Company lowered HCA Healthcare from an “equal weight” rating to an “underweight” rating and decreased their target price for the stock from $400.00 to $320.00 in a research report on Monday, November 25th. One analyst has rated the stock with a sell rating, three have given a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $385.67.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.